To hear about similar clinical trials, please enter your email below
Trial Title:
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients
NCT ID:
NCT05733026
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Conditions: Keywords:
Doxorubcin
Breast cancer
Cardiotoxicity
Gene polymorphism
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Recent advances in technologies, such as microarray and high-throughput sequencing,
represented a deeper understanding of molecular biology, especially noncoding RNA
(ncRNA). It was found that there are only <2 % of the total genome sequence as
protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the
past, non-protein-coding RNAs were known as "transcription noise," but now it is obvious
that ncRNAs play a crucial regulatory role in cell differentiation and organism growth
and metabolism.
Criteria for eligibility:
Study pop:
Metastatic and localized breast cancer patients treated with Doxorubicin
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Metastatic and localized breast cancer patients treated with Doxorubicin among
chemotherapeutic protocol.
- Measurable disease.
- Age of 18 years to 80 years.
- The women of childbearing age must use an effective contraception for the duration
of the study.
Exclusion Criteria:
- Breast cancer patients who had undergone radiotherapy or chemotherapy.
- Pregnant and lactating females.
- History of allergic reactions attributed to compounds of similar chemical or
biologic composition to chemotherapeutic agents used.
- Any other medical or psychiatric condition or severe or chronic laboratory
abnormality making the inclusion of the patient in the study inappropriate in the
opinion of the investigator.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Ain Shams University
Address:
City:
Cairo
Zip:
11315
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Neven Sarhan, PhD
Email:
sarhanneven@gmail.com
Start date:
August 1, 2020
Completion date:
April 1, 2023
Lead sponsor:
Agency:
Ain Shams University
Agency class:
Other
Source:
Ain Shams University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05733026
